EGFR and non-small cell lung carcinoma: So far, first generation TKIs (erlotinib, gefitinib and icotinib), second generation TKIs (afatinib) and third generation TKIs (osimertinib) have already been approved for the treatment for advanced NSCLC harboring EGFR activating mutations.